Full access to Entrepreneur for $5
Subscribe

Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA

Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.

By
This story originally appeared on Zacks

Myovant Sciences MYOV recently announced that the FDA has accepted for review a supplemental new drug application (sNDA) for Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg).

- Zacks

The drug is being jointly developed and commercialized by Myovant and partner Pfizer PFE in the United States.

The sNDA is seeking approval of the drug for the management of moderate to severe pain associated with endometriosis. The FDA has set a target action date of May 6, 2022.

The sNDA is supported by results from the phase III SPIRIT program. It included two multinational, replicate clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with pain associated with endometriosis for 24 weeks, and an open-label extension study for eligible women who completed either SPIRIT 1 or SPIRIT 2 through one year.

We remind investors that the FDA approved Myfembree as the first and only once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. It was launched in mid-June 2021.  The approval triggered a $100.0 million regulatory milestone payment from Pfizer, which the company received in July 2021.

Myovant’s shares have declined 9.1% so far this year against the industry’s growth of 1.3%.

 

Zacks Investment Research

Image Source: Zacks Investment Research

A potential label expansion of the drug will boost the company’s growth.

Earlier, in May, the FDA placed a partial clinical hold on phase III SERENE study evaluating Myfembree for the prevention of pregnancy, pending certain study protocol modifications. In July 2021, Myovant provided an amended study protocol for the SERENE study to the agency.

Myovant has another approved drug in its portfolio, Orgovyx (relugolix), which was approved by the FDA in 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer.

Myfembree is relugolix combination tablet. In July 2021, the European Commission also approved the same under the brand name Ryeqo. 

Zacks Rank & Stocks to Consider

Myovant currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks are Regeneron Corporation REGN and Moderna MRNA, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Earnings estimates for Regeneron have moved up 62 cents for 2021 in the past 60 days.  The stock is up 33.8% year to date.

Earnings estimates for Moderna have moved up 17 cents for 2021 in the past 30 days.  The stock is up 336.4% year to date.







 



Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly. 

See 3 crypto-related stocks now >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

 

Pfizer Inc. (PFE): Free Stock Analysis Report

 

Moderna, Inc. (MRNA): Free Stock Analysis Report

 

Myovant Sciences Ltd. (MYOV): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research